188 related articles for article (PubMed ID: 31277422)
1. Activating Mutations in
Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
[TBL] [Abstract][Full Text] [Related]
3. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
[TBL] [Abstract][Full Text] [Related]
4. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
5. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed.
Abadie J; Hédan B; Cadieu E; De Brito C; Devauchelle P; Bourgain C; Parker HG; Vaysse A; Margaritte-Jeannin P; Galibert F; Ostrander EA; André C
J Hered; 2009; 100 Suppl 1():S19-27. PubMed ID: 19531730
[TBL] [Abstract][Full Text] [Related]
7. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma.
Prouteau A; Denis JA; De Fornel P; Cadieu E; Derrien T; Kergal C; Botherel N; Ulvé R; Rault M; Bouzidi A; François R; Dorso L; Lespagnol A; Devauchelle P; Abadie J; André C; Hédan B
Sci Rep; 2021 Jan; 11(1):877. PubMed ID: 33441840
[TBL] [Abstract][Full Text] [Related]
9. Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.
Hu B; Patel JL; Tao R; Cannon RB; Monroe M; Goyal G
J Natl Compr Canc Netw; 2022 Mar; 20(6):618-621. PubMed ID: 35325867
[TBL] [Abstract][Full Text] [Related]
10. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
11. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
[TBL] [Abstract][Full Text] [Related]
12. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
[TBL] [Abstract][Full Text] [Related]
13. Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Hoffmann L; Coras R; Kobow K; López-Rivera JA; Lal D; Leu C; Najm I; Nürnberg P; Herms J; Harter PN; Bien CG; Kalbhenn T; Müller M; Pieper T; Hartlieb T; Kudernatsch M; Hamer H; Brandner S; Rössler K; Blümcke I; Jabari S
Acta Neuropathol; 2023 Jun; 145(6):815-827. PubMed ID: 36973520
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
15. Causes of death and the impact of histiocytic sarcoma on the life expectancy of the Dutch population of Bernese mountain dogs and Flat-coated retrievers.
Erich SA; Rutteman GR; Teske E
Vet J; 2013 Dec; 198(3):678-83. PubMed ID: 24231621
[TBL] [Abstract][Full Text] [Related]
16.
Hill KS; Roberts ER; Wang X; Marin E; Park TD; Son S; Ren Y; Fang B; Yoder S; Kim S; Wan L; Sarnaik AA; Koomen JM; Messina JL; Teer JK; Kim Y; Wu J; Chalfant CE; Kim M
Mol Cancer Res; 2019 Feb; 17(2):583-593. PubMed ID: 30355677
[TBL] [Abstract][Full Text] [Related]
17. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
[TBL] [Abstract][Full Text] [Related]
18. The intratumor heterogeneity of TP53 gene mutations in canine histiocytic sarcoma.
Asada H; Ichii O; Tomiyasu H; Uchida K; Chambers JK; Goto-Koshino Y; Ohno K; Kon Y; Tsujimoto H
J Vet Med Sci; 2019 Mar; 81(3):353-356. PubMed ID: 30662044
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Hypomorphic
Meek K; Yang YT; Takada M; Parys M; Richter M; Engleberg AI; Thaiwong T; Griffin RL; Schall PZ; Kramer AJ; Yuzbasiyan-Gurkan V
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292578
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
